drugset / Trial / NCT05586815

Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection

NCT05586815

Phase 4 Unknown 94 enrolled Mahidol University
RandomizedParallel-groupDouble-blindTreatment

Summary

Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients. It can acquire resistance to all classes of antibiotics (multidrug resistance, MDR) except an 'old' drug, colistin, which may be the only therapeutic option. The addition of minocycline to colistin has been shown to be synergistic in vitro, and may be promising in vivo, but this combination has not been limited to case report or case series in comparison with colistin alone.

Timeline

Start
2023-01-10
Primary completion
2024-01-31
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Colistin Other / unclassified 150 mg Intravenous
Subject Minocycline Small molecule 200 mg Oral